ZUG, Switzerland, 06 Dec. 11, 2022 (GLOBE NEWSWIRE) — nChain, one of the world’s leading blockchain solutions companies, today announces its partnership with Hataali, the world’s leading cell and gene therapy platform from ATMPS Ltd. The partnership will see nChain’s Data Integrity Platform provide Hataali with access to the most scalable and secure blockchain unprecedented in precision medicine.
Hataali is the most advanced and regulatory compliant medical data sharing platform for personalized medicines in the advanced therapy medicines industry. A unique, patented platform that offers the most comprehensive capabilities and features.
The Hataali platform enables all cell and gene therapy partners, from hospitals and laboratories, to clinics and specialist couriers, to communicate and coordinate in real time. The platform is a configurable solution that enables personalized medicine partner organizations to ensure that the data required for optimal patient outcomes can be shared between parties in a secure, confidential and regulatory compliant manner using advanced distributed ledger technology.
Hataali, winner of the 2022 CPHI Pharma Award and BioNow Award, is a true end-to-end solution that provides full transparency of the treatment process by maintaining an immutable record of the full chain of custody, identity and condition, demonstrating who is responsible and what was done at each stage of the process.
“Instant authorization, interoperability and analysis of data, securely between healthcare institutions, can greatly improve treatment efficiency and ensure patient safety. There is so much innovation in medicine personalized right now, but the full benefits of these treatments cannot be realized if our data infrastructure lags behind and cannot reach its full potential with our all-digital Hataali platform. more important for organizations that have become cost conscious and are looking for efficiency,” said Raja Sharif, Founder and CEO of ATMPS Ltd.
He added, “We are delighted to partner with nChain to integrate our platform providing access to their blockchain which we believe provides a best-in-class solution for data integrity, which is paramount in healthcare. health, and even more with regard to precision medicine. .”
Since 2015, nChain has focused on developing solutions and inventions for using enterprise blockchain and meeting the data management needs of all industries. nChain’s Data Integrity Platform provides businesses and governments with access to the benefits of tamper-proof documents, auditable logs, and integrated key management in APIs, allowing organizations to focus on collecting and analyzing data rather than securing it.
“The time has come for us to rethink the approach to the utility and safety of patient data. The rails of the healthcare system deserve as much innovation as the treatments themselves, if not the healthcare providers will not be effective in delivering these treatments. We are proud to partner with an organization at the forefront of the revolution in the delivery of cell and gene therapies, and we are committed to helping them make a difference in the lives of their patients,” commented nChain CEO Hakan Yuksel.
ATMPS Ltd provides patented advanced technical solutions for healthcare companies in the advanced therapy medicines sector, including CAR-T treatments, stem cells and gene treatments. ATMPS has a unique distributed ledger solution that provides immutable, incorruptible data and automation capabilities. The solution is operational, configurable and can provide data analysis modules. It can integrate with all LIMS, MES and legacy solutions. It provides full chain of custody, identity and status of the samples, processes and assets it tracks. It also plans and coordinates supply chain participants, while giving them information at the same time, in real time, from a “single source of truth”. For more information, please visit the ATMPS website at https://www.atmps.net.
nChain is one of the world’s leading blockchain technology companies and was recently voted one of the top 100 most innovative companies in the world. We offer software, consulting services and IP licensing for clients in various industries looking to benefit from the security and scalability of blockchain. Our mission is to secure the internet of value. Founded in 2015, nChain employs over 250 people, holds over 400 patents, and is the software developer of Bitcoin SV Node, Teranode, LiteClient, and more.
Director, Marketing and Communications
This content was posted through the press release distribution service on Newswire.com.
#nChain #partners #ATMPS #propel #worldleading #cell #gene #therapy #platform #Hataali